Since its formation in early 2008, Astrogenetix has worked closely with NASA to fully utilize the International Space Station, one of NASA’s primary priorities. To date, the company has flown on six shuttle missions performing drug development in microgravity. 

The discovery of a human vaccine candidate for salmonella represents the world’s first commercially sponsored vaccine development program founded on novel discovery in microgravity and a key milestone for the space and biotechnology industries.

  • 1993: Starting with Endeavour’s launch during STS-57, Astrogenetix’s parent company, Astrotech (formerly SPACEHAB), began providing cargo carriers and habitat & laboratory modules to NASA.
  • 2005: The NASA Authorization Act designated a portion of the International Space Station (ISS) as a National Laboratory enabling non-governmental entities to conduct research and development and potentially industrial processing on board the ISS.
  • 2008: Parent company Astrotech signed a Space Act Agreement (SAA) with NASA, allowing Astrogenetix to conduct its ground breaking research in microgravity. 
  • 2009: Astrogenetix research yielded a possible salmonella vaccine during the Space Shuttle Discovery (STS-128) mission to the International Space Station. 
  • 2011: A new Space Act Agreement was signed, allowing Astrogenetix to continue utilizing the International Space Station as a national laboratory. 
  • 2016: The Company is currently in the process of developing vaccine candidates in microgravity, with a focus on salmonella and methicillin-resistant Staphylococcus aureus (MRSA).


Space Act Agreements

2007 - 2010

For Commercial Space Transportation Capabilities

2008 - 2011
For Utilization of the International Space Station As A National Lab

2011 - 2016
For Utilization of the International Space Station As A National Lab

Copyright © Astrogenetix Corporation. All rights reserved.